Literature DB >> 14595463

Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system.

Angela Maria Werneck Barreto1, Joselba Borges Melo Araújo, Reginalda Ferreira de Melo Medeiros, Paulo César de Souza Caldas.   

Abstract

In order to evaluate the Organon Teknika MB/BacT system used for testing indirect susceptibility to the alternative drugs ofloxacin (OFLO), amikacin (AMI), and rifabutin (RIF), and to the usual drugs of standard treatment regimes such as rifampin (RMP), isoniazid (INH), pyrazinamide (PZA), streptomycin (SM), ethambutol (EMB), and ethionamide (ETH), cultures of clinical specimens from 117 patients with pulmonary tuberculosis under multidrug-resistant investigation, admitted sequentially for examination from 2001 to 2002, were studied. Fifty of the Mycobacterium tuberculosis cultures were inoculated into the gold-standard BACTEC 460 TB (Becton Dickinson) for studying resistance to AMI, RIF, and OFLO, and the remaining 67 were inoculated into Lowenstein Jensen (LJ) medium (the gold standard currently used in Brazil) for studying resistance to RMP, INH, PZA, SM, EMB, and ETH. We observed 100% sensitivity for AMI (80.8-100), RIF (80.8-100), and OFLO (78.1-100); and 100% specificity for AMI (85.4-100), RIF (85.4-100), and OFLO (86.7-100) compared to the BACTEC system. Comparing the results obtained in LJ we observed 100% sensitivity for RMP (80-100), followed by INH-95% (81.8-99.1), EMB-94.7% (71.9-99.7), and 100% specificity for all drugs tested except for PZA-98.3 (89.5-99.9) at 95% confidence interval. The results showed a high level of accuracy and demonstrated that the fully automated, non-radiometric MB/BacT system is indicated for routine use in susceptibility testing in public health laboratories.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595463     DOI: 10.1590/s0074-02762003000600020

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

1.  Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy.

Authors:  Sean P Fitzwater; Luz Caviedes; Robert H Gilman; Jorge Coronel; Doris LaChira; Cayo Salazar; Juan Carlos Saravia; Krishna Reddy; Jon S Friedland; David A J Moore
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

2.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

3.  Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pushpendra Singh; Clement Wesley; G P S Jadaun; Sunil Kumar Malonia; R Das; P Upadhyay; J Faujdar; P Sharma; P Gupta; Abhay Kumar Mishra; Kalpana Singh; D S Chauhan; V D Sharma; U D Gupta; K Venkatesan; V M Katoch
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

4.  Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.

Authors:  Anandi Martin; Andrea von Groll; Krista Fissette; Juan Carlos Palomino; Francis Varaine; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2008-10-22       Impact factor: 5.948

Review 5.  Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.

Authors:  Louis Grandjean; David A J Moore
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

6.  A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action.

Authors:  Charlotte Louise Hendon-Dunn; Kathryn Sarah Doris; Stephen Richard Thomas; Jonathan Charles Allnutt; Alice Ann Neville Marriott; Kim Alexandra Hatch; Robert James Watson; Graham Bottley; Philip David Marsh; Stephen Charles Taylor; Joanna Bacon
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Blood agar validation for susceptibility testing of isoniazid, rifampicin, ethambutol, and streptomycin to Mycobacterium tuberculosis isolates.

Authors:  Ahmet Yilmaz Coban
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.